CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy
ChemMedChem · 29.07.2026 · 21 (14)
DOI: 10.1002/cmdc.70396 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 23.07.2026. Verfasst von Youngheun Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, Sogang University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Celecoxib, Hyaluronan Receptors, Hyaluronic Acid, Melitten. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Education, Science, and Technology, Republic of Korea and the Ministry of Food and Drug Safety grant, Republic of Korea.
Abstract (Originalsprache)
Activated macrophages are key effector cells in inflammatory diseases, but the therapeutic use of membrane‐active agents such as melittin (MEL) is limited by nonspecific cytotoxicity and hemolysis. Here, we developed a hyaluronic acid (HA)‐coated MEL‐based polymersome (PMHA) for CD44‐targeted codelivery of MEL and celecoxib (CXB). MEL was incorporated into the vesicular membrane, whereas CXB was loaded into the hydrophobic domain. PMHA showed a hydrodynamic diameter of 265.5 ± 1.6 nm, a zeta‐potential of −21.14 ± 1.1 mV, a CXB encapsulation efficiency of 70.81 ± 4.18%, and a drug loading capacity of 12.87 ± 1.92%. In lipopolysaccharide (LPS)‐stimulated RAW 264.7 macrophages, anti‐CD44 antibody blocking reduced Alexa Fluor 647‐labeled PMHA uptake by approximately 37.5%, supporting HA–CD44‐mediated internalization. PMHA reduced MEL‐associated cytotoxicity and hemolytic activity and enabled pH‐responsive CXB release. Codelivery of MEL and CXB suppressed cyclooxygenase‐2 (COX‐2) and tumor necrosis factor‐α (TNF‐α) expression, with combination index (CI) values of 0.48 and 0.67, respectively. These findings support further evaluation of PMHA as a macrophage‐targeted anti‐inflammatory nanoplatform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, Sogang University, Seoul, Republic of Korea.
- Department of Biomedical Engineering, Sogang University, Seoul, Republic of Korea.
Förderung
- Ministry of Education, Science, and Technology
- Republic of Korea and the Ministry of Food and Drug Safety grant
- Republic of Korea
- Ministry of Education, Science and Technology
Zitieren
APA
Cho, Y., Kim, J., Moon, J., Nam, S., Kim, J., & Kim, H. (2026). CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy. ChemMedChem, 21(14). https://doi.org/10.1002/cmdc.70396
Vancouver
Cho Y, Kim J, Moon J, Nam S, Kim J, Kim H. CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy. ChemMedChem. 2026;21(14). doi:10.1002/cmdc.70396
BibTeX
@article{Cho2026,
author = {Cho, Youngheun and Kim, Junmin and Moon, Jooho and Nam, Soobin and Kim, Junhyung and Kim, Hyuncheol},
title = {CD44‐Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid‐Coated Polymersomes for Synergistic Anti‐Inflammatory Therapy},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {14},
doi = {10.1002/cmdc.70396}
}
EUVIMED